Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: TMDX.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

TransMedics Group (TMDX) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$97

+11.9%

2031

5-Year

BUY

$183

+111.8%

Published batch insight

Integrated Organ Perfusion Network Balances High Capital Intensity Against Monopolistic Moats

Synthesizing input evaluations reveals high consensus that clinical dominance and turnkey aviation infrastructure create an insurmountable distribution moat. Sharp divergence persists regarding whether elevated flight operating expenses and capital intensity will permanently cap operating margins or yield substantial operating leverage at scale.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), J.P. Morgan (Titan), Warren Buffett (Value Purist), Machiavelli (Insider), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist), Superintelligence (Anthropologist), Elon Musk (Visionary), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in TransMedics Group at the forecast anchor (2026-09-18): $21,176 in five years versus $13,892 for S&P 500 benchmark.

TransMedics Group · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for TransMedics Group compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 86.42 USD1-year price return: +11.87%5-year price return: +111.76%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	86.71	+0.34%	+0.34%	Q3 results confirm solid procedural volume expansion across liver and heart programs, but elevated jet fuel expenses and executive transition noise keep quarterly operating margins compressed, resulting in flat-to-modest equity performance.
Q1 2027	89.81	+3.58%	+3.92%	Full-year 2026 results confirm top-line execution near $745M. Normalization of reported trailing net income without prior tax credits tempers multiple expansion, though constructive 2027 guidance establishes a resilient valuation floor.
Q2 2027	94.09	+4.77%	+8.88%	Sequential gross margin stabilization emerges as fuel surcharges take effect and flight route scheduling improves across domestic hubs. Core liver cassette replenishment offsets initial PAD Aviation European integration costs.
Q3 2027	96.68	+2.74%	+11.87%	Summer procurement seasonality and elevated clinical trial expenditures for ENHANCE and DENOVO produce modest margin consolidation, counterbalanced by steady double-digit procedural volume growth across certified transplant centers.
Q4 2027	102.90	+6.43%	+19.06%	Strong year-end transplant volume combines with initial commercial cross-border flight missions in Western Europe. Growing cassette pull-through improves service unit economics, prompting moderate institutional accumulation.
Q1 2028	107.51	+4.49%	+24.41%	Full-year 2027 earnings demonstrate sequential operating margin recovery toward 15%. Investor attention pivots to the approaching June 2028 convertible note maturity, keeping valuation multiples disciplined despite solid cash generation.
Q2 2028	112.06	+4.23%	+29.67%	TransMedics addresses its $460M convertible notes through structured refinancing. Resolving balance-sheet overhang without punitive equity dilution triggers a relief rally, supported by accelerating European operational contributions.
Q3 2028	116.66	+4.11%	+34.99%	Optimized aviation route density across domestic corridors lowers deadhead flight hours. Steady recurring consumable cassette sales sustain operating profits, absorbing scheduled aircraft maintenance without cash flow impairment.
Q4 2028	123.54	+5.89%	+42.95%	Pivotal clinical progress across heart and lung trials reinforces clinical exclusivity over static cold storage. Fiscal 2028 concludes with revenue approaching $1B, validating multi-organ platform adoption.
Q1 2029	129.27	+4.64%	+49.58%	Full-year 2028 financials confirm operating margins approaching 18% as fixed aviation overhead amortizes. Initial premarket regulatory milestones for OCS Kidney attract long-term healthcare growth allocators.
Q2 2029	135.82	+5.07%	+57.16%	Submission of formal PMA filings for OCS Kidney sparks multiple expansion as the addressable market narrative widens. European NOP operations achieve operating breakeven, demonstrating successful international model exportability.
Q3 2029	139.53	+2.73%	+61.46%	Transplant center budgeting cycles and competitive marketing from hypothermic perfusion alternatives create minor pricing friction, temporarily moderating quarterly sequential earnings growth in standard donor indications.
Q4 2029	146.86	+5.25%	+69.93%	Robust fourth-quarter organ retrievals and expanding DCD heart utilization drive record consumable kit shipments. Free cash flow generation accelerates, enabling internal funding of next-generation console tooling.
Q1 2030	153.46	+4.50%	+77.57%	Annual 2029 results validate durable twenty percent operating margins. Cash reserves accumulate, reinforcing balance sheet strength and proving that captive logistics creates an enduring competitive barrier.
Q2 2030	159.07	+3.65%	+84.06%	Regulatory clearance for OCS Kidney initiates controlled commercial deployment across high-volume renal transplant centers. Incremental consumable sales leverage existing flight infrastructure, expanding gross profit margins.
Q3 2030	162.07	+1.88%	+87.53%	Routine periodic aircraft engine overhauls and commercial launch expenditures for kidney perfusion induce modest margin digestion, allowing the market to consolidate substantial multi-year share price gains.
Q4 2030	168.72	+4.11%	+95.23%	Accelerating kidney cassette adoption combines with mature liver franchise dominance. Procedural volume compounds predictably, driving full-year revenue well above $1.3B and lifting operating cash flows.
Q1 2031	174.04	+3.15%	+101.39%	Full-year 2030 financial reporting showcases normalized operating margins exceeding 22%. European operations deliver sustained profit contributions, broadening the enterprise beyond its domestic foundation.
Q2 2031	177.78	+2.15%	+105.72%	Mature fleet operations achieve peak logistics efficiency. Established standard-of-care status in warm machine perfusion insulates the company from macro volatility, supporting steady earnings compounding.
Q3 2031	183.00	+2.94%	+111.76%	TransMedics concludes the forecast period established as an indispensable organ procurement utility. Valuation settles at a mature infrastructure-like multiple supported by robust recurring cash generation.

TransMedics presents a compelling multi-organ infrastructure platform transitioning through an intensive capital-digestion phase. The core economic argument rests on the company's captive National OCS Program (NOP), where vertical integration of surgical retrieval and an owned 22-aircraft fleet creates an insurmountable distribution moat. Clinical superiority in resuscitating donation-after-circulatory-death (DCD) hearts and livers drives resilient 20% top-line compounding, protected by Medicare's statutory organ acquisition pass-through reimbursement. However, the valuation remains highly sensitive to cost-of-capital headwinds and aviation asset drag. The market must normalize for the non-recurring $82.8M tax allowance release in 2025, revealing true trailing operating earnings near $68M. The strongest counterargument highlights the economic penalty of running a dedicated air carrier: service revenue (41% of sales) structurally dilutes gross margins, while unhedged jet fuel volatility, aircraft maintenance, and emerging hospital-based normothermic regional perfusion (NRP) protocols cap terminal margins below management's 30% target.

Key insights

Captive aviation assets transform fixed logistics overhead into an expanding switching barrier that standalone hardware competitors cannot breach without massive capital destruction.
Growth mix dilution poses structural friction: service revenues compound faster than high-margin consumable cassettes, permanently altering the normalized operating margin profile.
Approaching 2028 convertible note maturities requires disciplined operational cash generation to prevent punitive debt refinancing in a higher-for-longer interest rate regime.

Deep Dive

Outside market consensus views TransMedics as a decelerating medtech pioneer that compromised its corporate quality by transforming into a capital-heavy regional airline. Sell-side commentary fixates on Q2 2026 GAAP net income contraction, ongoing CFO turnover, and margin dilution from jet fuel and R&D outlays, anchoring on the belief that running aviation logistics permanently caps operating profitability below historical device industry standards.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underprices TransMedics' durable operational edge by mistaking a planned infrastructure reinvestment phase for terminal margin decay. While the market overreacts to the optical drop from tax-distorted 2025 earnings, it overlooks how captive aviation creates an inescapable distribution monopoly over nationwide donor recovery. The strongest challenge is that service revenue genuinely carries lower gross margins than consumables; however, route-density optimization will unlock substantial operating leverage as case volumes scale.

Repricing catalyst

Sequential gross margin stabilization above 60% and operating margin recovery toward 16% across 2027 filings will trigger market repricing. Observable inflection points include the clinical data readout and IDE milestones for the OCS Kidney platform alongside operating breakeven in European flight operations via PAD Aviation. These operational receipts will prove to skeptical analysts that aviation logistics dilutes fixed costs rather than permanently impairs profitability.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of 3.75%-4.00% policy rates and elevated jet fuel prices acts as a tangible operational headwind. High interest rates raise the equity hurdle rate and refinancing costs for the 2028 convertible notes, while expensive fuel compresses flight margins. However, end-stage organ failure is clinically non-discretionary, completely insulating core procedure volumes from macroeconomic deceleration.

Published consensus context

Advisor disagreement

The primary disagreement centers on the terminal margin profile and capital intensity of TransMedics' hybrid model. Bullish perspectives argue that aviation fleet investments represent a completed capital phase that will unlock operating margins above 25% through route density. Conversely, conservative analysts view owned aviation as a perpetual operational friction where jet fuel, aircraft depreciation, and crew payroll permanently cap operating margins near 14% to 16%. Observing whether quarterly service gross margins can sequentially surpass 40% while maintaining volume growth will definitively resolve whether logistics acts as an operating flywheel or a permanent margin anchor.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Captive Aviation Logistics Distribution Moat: Controlling 22 dedicated transport aircraft allows TransMedics to cover over 80% of domestic National OCS Program missions internally. This end-to-end integration eliminates charter broker markups and guarantees surgical retrieval timing. Standalone device makers cannot replicate this physical distribution network without immense capital destruction, locking in dominant hospital market share. Expected impact: +34%.
DCD Donor Organ Utilization Expansion: Secular clinical adoption of donation-after-circulatory-death (DCD) donors drives steady volume expansion across heart and liver indications. Because marginal organs deteriorate rapidly in static cold storage, warm perfusion is becoming the clinical standard of care. This biological necessity compounds high-margin recurring single-use cassette sales at roughly 20% annually. Expected impact: +28%.
Statutory Organ Acquisition Pass-Through Reimbursement: TransMedics' pricing power is structurally insulated by Medicare Title XVIII provisions, allowing certified transplant centers to pass organ procurement and transportation expenses directly to federal trust funds without standard DRG caps. Regulatory mandates penalizing organ discards further incentivize transplant centers to deploy OCS regardless of upfront procedure costs. Expected impact: +22%.
Aviation Fleet Density Operating Leverage: Having absorbed initial aircraft acquisition capital expenditures, TransMedics is shifting toward flight asset optimization. Increasing annual flight hours per airframe amortizes fixed pilot compensation and maintenance overhead across higher mission counts. This route-density scaling expands service gross margins toward 38%, transforming transport logistics into an accretive earnings contributor. Expected impact: +20%.

Top frictions and headwinds

Aviation Asset Intensity Margin Dilution: Service revenue expanding to 41% of sales structurally dilutes blended profitability because logistics generates lower gross margins than consumable cassettes. Operating an owned air fleet exposes earnings to mandatory FAA maintenance overhauls, pilot payroll inflation, and unhedged jet fuel price spikes, capping consolidated operating margins below historic software-like expectations. Expected impact: -20%.
Normothermic Regional Perfusion Clinical Substitution: Transplant centers are increasingly deploying hospital-based normothermic regional perfusion (NRP) using existing ECMO circuits for in situ DCD donor resuscitation. Because NRP bypasses TransMedics' expensive proprietary disposables and private flight charters for regional recoveries, it caps OCS volume penetration in cost-conscious academic medical centers. Expected impact: -16%.
Convertible Debt Refinancing Hurdle: TransMedics faces a $460 million convertible senior note maturity on June 1, 2028, carrying a 1.50% coupon. In an elevated monetary policy regime with benchmark yields near 4%, refinancing or cash-settling this obligation threatens to consume operational cash flow, raise interest expense, or impose equity dilution on existing shareholders. Expected impact: -15%.
Front-Loaded Clinical Research Expenditure Drag: Quarterly R&D expenses nearly doubled year-over-year to over $31 million in mid-2026 to support next-generation console architectures and pivotal trials. While necessary to expand indications, heavy trial-related outlays and clinical solution costs depress near-term GAAP operating income and return on capital during the intermediate pipeline gestation window. Expected impact: -12%.

Tail risks

Catastrophic Aviation Fleet Grounding Directive: A fatal crash or severe airworthiness directive across TransMedics' dedicated jet fleet prompting an emergency FAA grounding would instantly paralyze the National OCS Program. Halting flight operations would strand donor organs, destroy customer clinical trust, spike liability insurance costs, and wipe out tens of millions in logistics revenue within months. Probability: +14%. Expected impact: -42%.
Medicare Organ Acquisition Reimbursement Cap: The Centers for Medicare and Medicaid Services could initiate targeted cost-containment audits restricting pass-through allowances for private air charter markups and perfusion disposables. Imposing fixed prospective payment limits would force transplant centers to absorb logistics cost overruns, triggering immediate clinical pushback and steep price discounting. Probability: +26%. Expected impact: -36%.

Tail opportunities

OCS Kidney Accelerated PMA Clearance: Securing accelerated FDA Premarket Approval for the OCS Kidney platform around 2028 would quadruple TransMedics' total addressable market, as kidney transplants exceed 25,000 annual US procedures. Commercialization would utilize the existing aviation network with negligible incremental transport capex, unlocking massive high-margin cassette pull-through and driving corporate operating margins above 25%. Probability: +35%. Expected impact: +52%.
Mandatory Federal Warm Perfusion Standard: Federal healthcare authorities could establish mandatory quality metrics penalizing organ procurement organizations for organ discard rates while providing enhanced DRG add-on payments for machine perfusion by 2028. Obsoleting static cold storage would eliminate hospital procurement discretion, locking in TransMedics as a statutory standard of care across nationwide organ recovery. Probability: +25%. Expected impact: +38%.

What to monitor

Thesis watchpoints

-- Confirmation requires adjusted operating margins rebounding above 16% alongside sequential service gross-margin expansion within the next four reporting quarters.

Key insights

Deterioration triggers if service revenue exceeds 45% of sales while consolidated gross margin falls below 57% across two consecutive quarters.
Reassessment demands immediate review if 2028 convertible debt refinancing requires punitive interest coupons exceeding 7% or dilutive equity issuance.

Company Financial Analysis

TransMedics Group Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

TransMedics has demonstrated powerful top-line revenue growth, expanding annual sales by 37.1% to $605.5 million in fiscal 2025 and continuing with 20.7% growth to $189.9 million in the second quarter of 2026. However, reported net income paints a confusing picture for investors. While 2025 headline net income reached $190.3 million, that figure was artificially boosted by a one-off, non-cash tax benefit of $82.8 million. Normalized earnings were closer to $68 million. In the first half of 2026, GAAP profits dropped sharply to $14.7 million as research spending nearly doubled to develop new kidney platforms and fleet maintenance costs increased. This decline does not mean customer demand is falling; underlying procedure volumes remain robust. Operating cash generation remains positive at $79 million over the trailing twelve months, showing that the core business is self-funding its heavy growth investments.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 605.5M	USD 190.3M	USD 133.6M
2024	USD 441.5M	USD 35.5M	USD -80.9M
2023	USD 241.6M	USD -25M	USD -192.1M
2022	USD 93.5M	USD -36.2M	USD -57.7M
2021	USD 30.3M	USD -44.2M	USD -32.4M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	26.2x	TTM	Native	USD / USD
2024	61.9x	TTM	Native	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

TransMedics exhibits a sharp divide between steady gross margins and fluctuating operating profits. Gross margins have held firm near 59.6%, demonstrating strong pricing power for single-use organ preservation cassettes. However, operating margin compressed from 17.9% in 2025 to 12.5% in mid-2026. This contraction is driven by two factors: lower-margin aviation logistics rising to 41% of total sales, and elevated jet fuel prices. This margin compression represents active business reinvestment rather than permanent deterioration. Single-use organ cassettes generate high gross profits, but flight logistics dilute corporate margins. Long-term profitability will depend on route density; as aircraft fly more missions per month and higher-margin kidney cassettes eventually launch, fixed transport costs will dilute, allowing operating margins to climb back toward the low-twenties percentage range.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 108.6M	17.9%	31.4%
2024	USD 37.5M	8.5%	8.0%
2023	USD -28.7M	-11.9%	-10.4%
2022	USD -31.4M	-33.6%	-38.8%
2021	USD -39.4M	-130.3%	-146.1%

Balance sheet and leverage

AI Review

On the surface, TransMedics appears to hold a fortress balance sheet, with roughly $473 million in cash and short-term liquidity alongside a current ratio of 7.14 at mid-2026. Total stockholders' equity reached $473 million, and headline debt-to-equity declined to 0.99. This substantial cash buffer provides crucial breathing room, ensuring the company can advance clinical trials without needing desperate equity raises. However, deeper inspection reveals significant structural commitments. The company carries $460 million in convertible notes that mature in June 2028, alongside substantial aircraft lease and facility obligations. Total financing commitments approach $862 million, leaving net financing obligations near $389 million. Refinancing the 2028 notes in a higher interest rate environment represents management's primary financial hurdle, requiring steady operational cash flow to avoid expensive borrowing or shareholder dilution.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 469.7M	USD 488.4M	USD 18.7M net cash	7.14x
2024	USD 518.3M	USD 336.7M	USD 181.6M net debt	8.30x
2023	USD 515.9M	USD 394.8M	USD 121.1M net debt	9.30x
2022	USD 67.6M	USD 201.2M	USD 133.6M net cash	10.66x
2021	USD 43.8M	USD 92.5M	USD 17M net cash	5.11x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has spent recent years transforming the company from a medical equipment seller into an integrated logistics network. Direct cash spending on equipment peaked at 29.4% of revenue in 2024 as TransMedics assembled its private fleet of 22 aircraft, before normalizing to 9.8% in 2025. In 2026, capital deployment shifted toward establishing a European flight hub through Germany-based PAD Aviation and leasing a centralized corporate campus. While operating aircraft requires ongoing engine maintenance and specialized inspections, owning transport infrastructure creates an insurmountable barrier against competitors who rely on commercial flights. Spending has migrated from buying planes into research and development, which climbed 98.5% year-over-year in the second quarter of 2026. The economic payoff depends on spreading these heavy fixed infrastructure expenses across significantly more transplant missions over the coming years.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 59.3M	USD 69.1M
2024	USD 129.7M	USD 56M
2023	USD 179.1M	USD 63.3M
2022	USD 11.9M	USD 26.8M
2021	USD 3.5M	USD 22.3M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	101	+13.2%	Not available	ORIGINAL
5Y	BUY	165	+118%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	81.23	87.35	90.74	14
+6M	March 18, 2027	78.82	90.68	95.27	14
+9M	June 18, 2027	82.76	95.07	102.89	14
+1Y	September 18, 2027	86.07	97.86	108.04	14
+15M	December 18, 2027	91.23	104.17	115.6	14
+18M	March 18, 2028	93.97	109.19	126	14
+21M	June 18, 2028	95.29	114.33	133.56	14
+2Y	September 18, 2028	101.96	118.47	135.09	14
+27M	December 18, 2028	106.72	125.62	141.36	14
+30M	March 18, 2029	103.51	132.12	154.21	14
+33M	June 18, 2029	108.69	138.91	166.38	14
+3Y	September 18, 2029	113.04	143.1	173.69	14
+39M	December 18, 2029	117.56	150.67	181.69	14
+42M	March 18, 2030	121.09	157.53	192.59	14
+45M	June 18, 2030	125.93	163.54	208	14
+4Y	September 18, 2030	127.21	166.53	201.76	14
+51M	December 18, 2030	133.57	173.44	211.85	14
+54M	March 18, 2031	136.27	178.79	220.4	14
+57M	June 18, 2031	140.36	182.59	229.21	14
+5Y	September 18, 2031	143.17	188.4	238.38	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

The Whistleblower

The Polymath

Gemini 3.8 Flash

Weight5.3/100

Clear focus on the fixed-cost absorption flywheel and clinical trial catalysts. However, it assigns insufficient probability to potential Medicare reimbursement pushback against bundled aviation transport logistics fees.

Skip to references

Research Provenance

References & Context

This TransMedics Group consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 48 deduplicated sources retained for this batch.

01Building a Safer, More Accountable Transplant System | HRSAhrsa.gov
02Modernizing the Transplant System Through Safety and Transparency | HRSAhrsa.gov
03From Haphazard to a Sustainable Normothermic Regional Perfusion Service: A Blueprint for the Introduction of Novel Perfusion Technologiesncbi.nlm.nih.gov
04Thoracoabdominal Normothermic Regional Perfusion: Real-world Experience and Outcomes of DCD Liver Transplantationncbi.nlm.nih.gov
05Real‐World Use of Normothermic Machine Perfusion in Liver Transplantation: A Multi‐Institutional Experience From the National Organ Perfusion Registry - PMCpmc.ncbi.nlm.nih.gov
0610-Ksec.gov
07TransMedics Group, Inc. - Form 10-Q - FY2026sec.gov
08TMDX Q2-2026 Earnings Call - Alpha Spreadalphaspread.com
09transmedics reports fourth quarter and full year 2025 financial resultsbarchart.com
10TransMedics Group Inc (TMDX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...finance.yahoo.com
11Why TransMedics Stock Is Sinking Today | The Motley Foolfool.com
12TMDX FRAUD ALERT: TransMedics Group, Inc. Investigated for Securities Fraud after Stock Drops 30% – Investors Urged to Contact BFA Law (NASDAQ:TMDX)globenewswire.com
13TMDX STOCK NEWS: TransMedics Group, Inc. 30% Stock Drop Prompts Fraud Investigation; Contact BFA Law if You Suffered Losses (NASDAQ:TMDX)globenewswire.com
14TransMedics Group Inc (TMDX) Stock Price & News - Google Financegoogle.com
15Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling By Investing.cominvesting.com

And 33 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2016-12-31–2025-12-31, 10 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.